Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Membrane type-1 matrix metalloprotein inhibitors and uses thereof

一种基质金属、膜型的技术，应用在蛋白酶抑制剂、肽/蛋白质成分、抗炎剂等方向

Inactive Publication Date: 2011-12-28
ANGLACHEM INC
View PDF14 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This process may involve the decomposition of the ECM structure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Membrane type-1 matrix metalloprotein inhibitors and uses thereof
  • Membrane type-1 matrix metalloprotein inhibitors and uses thereof
  • Membrane type-1 matrix metalloprotein inhibitors and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0262] Preparation of MT1-MMP-derived peptides

[0263] In carrying out the experiments described in the Examples below, the following peptides were prepared. First, a peptide with the sequence of the cytoplasmic domain of MT1-MMP (RRHGTPRRLLLYCQRSLLDKV; SEQ ID NO: 117) and a non-phosphorylatable form of this peptide (RRHGTPRRLLFCQRSLLDKV; SEQ ID NO: 118) were prepared, wherein in combination with human MT1- The tyrosine at the position corresponding to amino acid 573 of the MMP sequence was replaced by phenylalanine. This non-phosphorylatable peptide was referred to as "M-14".

[0264] Additionally, a peptide with the M-14 sequence fused to the third helix of the cell-penetrating tentaclepedin homology domain (RQIKIWFQNRRMKWKK; SEQ ID NO: 119) was made. This fusion peptide is called ACM-14 and has the sequence: Biotin-Ahx-RQIKIWFQNRRMKWKK-RRHGTPRRLLFCQRSLLDKV (SEQ ID NO: 176). A version of the fusion peptide in which the cytoplasmic MT1-MMP domain sequence was scrambled wa...

Embodiment 2

[0266] Expression of Y573F MT1-MMP inhibits tumor growth

[0267] HT1080 fibrosarcoma cells were stably transfected with WT MT1-MMP or Y573F MT1-MMP. HT1080 cells are very aggressive cancer cells that express elevated levels of MT1-MMP. These two groups of cells were transplanted subcutaneously into athymic nude mice, and tumor growth was monitored. Such as figure 2 As shown, cells expressing the cytoplasmic domain of MT1-MMP exhibited significant tumor growth, whereas no tumor growth was observed in mice receiving cells expressing the Y573F mutant.

Embodiment 3

[0269] ACM-14 and scACM-14 efficiently taken up by fibrosarcoma cells

[0270] To determine whether ACM-14 and scACM-14 were able to enter tumor cells, HT-1080 fibrosarcoma cells were incubated with each peptide (1 μM) for 1 hr, and peptide uptake was analyzed by immunofluorescence and confocal microscopy. Such as image 3 As shown, ACM-14 and its promiscuous form (scACM-14) were visualized in this cell, indicating efficient and rapid cellular uptake.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Based on the discovery that a soluble polypeptide including a nonphosphorylatable form of the MT1-MMP cytoplasmic domain is capable of inhibiting MT1-MMP in a dominant negative manner, the present invention provides compositions including MT1-MMP inhibitors such as peptide inhibitors, and methods for treating diseases associated with MT1-MMP activity. Such diseases include cancer, arthritis, and heart disease, and vascular disease.

Description

technical field [0001] The present invention relates to compounds capable of inhibiting membrane type-1 metalloprotease (MT1-MMP or MMP-14), and methods of using these compounds to treat diseases such as cancer, heart and vascular diseases, and arthritis. Background technique [0002] Disease processes, including cancer, cardiac and vascular diseases, and arthritis, involve the breakdown and remodeling of the extracellular matrix (ECM). [0003] Cancer is a disease marked by the uncontrolled growth of abnormal cells. Cancer cells overcome the barriers imposed on normal cells with a limited lifespan to grow indefinitely. As cancer cells continue to grow, genetic changes may continue to occur until the cancer cells exhibit a more aggressive growth phenotype. If left untreated, metastasis, the spread of cancer cells to distant areas of the body through the lymphatic system or bloodstream, can then damage healthy tissue. [0004] Cancer metastasis requires that cancer cells l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N9/64A61K38/10A61K38/48A61K38/57A61P19/02A61P35/00C07K14/81
CPCC12N9/6491A61K38/4886A61P9/00A61P9/10A61P9/12A61P19/02A61P19/08A61P29/00A61P35/00A61P35/02
Inventor 理查德·贝利沃丹尼斯·金格拉斯卡里纳·恩亚伦多
Owner ANGLACHEM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com